Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication.

abstract：:In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a fa...

journal_title：Expert review of neurotherapeutics

authors： Paolino MC,Ferretti A,Papetti L,Villa MP,Parisi P

更新日期：2016-01-01 00:00:00

abstract：:Recent morphometric MRI studies have investigated brain volume abnormalities associated with the diagnosis of Alzheimer's disease (AD) using voxel-based morphometry (VBM). This technique allows the assessment of gray matter volumes in subjects with AD or related conditions compared with healthy controls in an automate...

journal_title：Expert review of neurotherapeutics

authors： Busatto GF,Diniz BS,Zanetti MV

更新日期：2008-11-01 00:00:00

abstract：:With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to ...

journal_title：Expert review of neurotherapeutics

authors： Bergamaschi R

更新日期：2006-03-01 00:00:00

abstract：:The term cervicogenic headache (CeH) describes a syndrome originating from the cervical spine. There are a variety of therapeutic approaches used for the management of CeH, but scientific evidence of their effectiveness is scarce. No medication drug has proven to be effective. The evidence for greater occipital nerve ...

journal_title：Expert review of neurotherapeutics

authors： Fernández-de-las-Peñas C,Cuadrado ML

更新日期：2014-01-01 00:00:00

abstract：:Management issues for patients with brain tumors include peritumoral edema, symptomatic seizures, venous thromboembolism, headache, pain, fatigue and neuropsychological complaints. Vasogenic edema is typically ameliorated with the lowest dose possible of corticosteroid. Seizures are managed with attention to additiona...

journal_title：Expert review of neurotherapeutics

authors： Daly FN,Schiff D

更新日期：2007-10-01 00:00:00

abstract：INTRODUCTION:Calcitonin Gene-Related Peptide (CGRP) has gradually emerged as a suitable therapeutic target to treat migraine. Considering the social and economic burden of migraine, it is fundamental to optimize the disease management with efficacious and safe treatments. In this scenario, drugs targeting GCRP, monoclo...

journal_title：Expert review of neurotherapeutics

authors： De Matteis E,Guglielmetti M,Ornello R,Spuntarelli V,Martelletti P,Sacco S

更新日期：2020-06-01 00:00:00

abstract：INTRODUCTION:Patients with multiple sclerosis (MS) may suffer from spasticity and pain during their disease course. Baclofen, dantrolene, diazepam and gabapentin have been used as first-line options to treat these conditions, with modest results. Medical use of marijuana smoking has bypassed traditional clinical trials...

journal_title：Expert review of neurotherapeutics

authors： Fragoso YD,Carra A,Macias MA

更新日期：2020-08-01 00:00:00

abstract：INTRODUCTION:Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer's disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to show statistically significant results supporting their clinica...

journal_title：Expert review of neurotherapeutics

authors： Amanatkar HR,Papagiannopoulos B,Grossberg GT

更新日期：2017-01-01 00:00:00

abstract：INTRODUCTION:Neurodegenerative processes occur from the beginning of multiple sclerosis, contribute to irreversible clinical disability and are only partially addressed by current disease-modifying therapies. Reliable quantification of neuro-axonal damage may contribute to improve the assessment of disease activity and...

journal_title：Expert review of neurotherapeutics

authors： Preziosa P,Rocca MA,Filippi M

更新日期：2020-08-01 00:00:00

abstract：:This article reviews the potential uses of complementary and alternative medicine (CAM) techniques for individuals with mood disorders. Mood disorders are among the most prevalent mental health issues today and there are many approaches towards their management. While many different types of medication are available, ...

journal_title：Expert review of neurotherapeutics

authors： Moss AS,Monti DA,Amsterdam JD,Newberg AB

更新日期：2011-07-01 00:00:00

abstract：:Neuroprotective therapy has been proposed for age-related neurodegenerative disorders, including Parkinson's disease. Inhibitors of type B monoamine oxidase (MAOB-Is), rasagiline and (-)deprenyl, are the most promising candidate neuroprotective drugs. Clinical trials of rasagiline in patients with Parkinson's disease ...

journal_title：Expert review of neurotherapeutics

authors： Naoi M,Maruyama W

更新日期：2009-08-01 00:00:00

abstract：:Parkinson's disease is a chronic neurodegenerative disorder leading to progressive motor impairment for which there is no cure. Currently, the diagnosis is made by the presence of cardinal motor features and several associated non-motor symptoms. However, at this point, the underlying neuropathological changes are alr...

journal_title：Expert review of neurotherapeutics

authors： Akhtar RS,Stern MB

更新日期：2012-12-01 00:00:00

abstract：:Transcranial magnetic stimulation (TMS) can directly stimulate the CNS, modifying the brain's plasticity to enhance the behavior of the paretic extremities. Studies with low-frequency repetitive TMS (rTMS) on the intact hemisphere and those with high frequencies on the affected hemisphere could increase the speed of m...

journal_title：Expert review of neurotherapeutics

authors： Málly J,Stone TW

更新日期：2007-02-01 00:00:00

abstract：INTRODUCTION:Mental illness has a chronic course of illness with a number of clinical manifestations. Affected individuals experience significant functional, emotional, cognitive, and/or behavioral impairments. The growing prevalence of mental illness has been associated with significant social and economic costs. Inde...

journal_title：Expert review of neurotherapeutics

authors： Gill H,Gill B,Chen-Li D,El-Halabi S,Rodrigues NB,Cha DS,Lipsitz O,Lee Y,Rosenblat JD,Majeed A,Mansur RB,Nasri F,Ho R,McIntyre RS

更新日期：2020-12-01 00:00:00

abstract：:Dual-task (DT) circumstances aggravate gait disorders in Parkinson's disease (PD) and are associated with an increased risk of falling and reduced functional mobility. Clinical rehabilitation guidelines for PD consider DT interventions as potentially hazardous and recommend avoiding them in daily life. The current art...

journal_title：Expert review of neurotherapeutics

authors： Strouwen C,Molenaar EA,Münks L,Keus SH,Bloem BR,Rochester L,Nieuwboer A

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, a...

journal_title：Expert review of neurotherapeutics

authors： Khan A,Corbett A,Ballard C

更新日期：2017-07-01 00:00:00

abstract：:Many antiepileptic drugs (AEDs) have therapeutic applications that extend beyond epilepsy to include neuropathic pain, migraine headaches and psychiatric disorders. The risk of some AEDs has been clearly established, but for newer drugs, small sample sizes and polytherapy exposures preclude a conclusive determination ...

journal_title：Expert review of neurotherapeutics

authors： Hill DS,Wlodarczyk BJ,Palacios AM,Finnell RH

更新日期：2010-06-01 00:00:00

abstract：:Non-pharmacological interventions have the potential to reduce cognitive decline and to improve psychosocial aspects in mild cognitive impairment and Alzheimer's dementia, and the absence of side effects makes them a favorable option also for preventive strategies. We provide an overview on recent studies involving co...

journal_title：Expert review of neurotherapeutics

authors： Herholz SC,Herholz RS,Herholz K

更新日期：2013-11-01 00:00:00

abstract：:Patients with von Hippel-Lindau disease (VHL) often harbor significant disease burden within the CNS, specifically craniospinal-axis hemangioblastomas and endolymphatic sac tumors (ELSTs). The majority (60-80%) of patients with VHL harbor hemangioblastomas, and 10-15% will develop ELSTs. Advances in the understanding ...

journal_title：Expert review of neurotherapeutics

authors： Wind JJ,Lonser RR

更新日期：2011-10-01 00:00:00

abstract：:Multiple sclerosis (MS) is an autoimmune disorder characterized by CNS inflammation, demyelination and cellular damage with atrophy. Most patients with MS initially present with a relapsing-remitting course, with periodic episodes of neurologic symptomatology that do not follow a predictable pattern. In order to maint...

journal_title：Expert review of neurotherapeutics

authors： Fox EJ

更新日期：2010-12-01 00:00:00

abstract：INTRODUCTION:Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and bleedin...

journal_title：Expert review of neurotherapeutics

authors： Arnao V,Riolo M,Tuttolomondo A,Pinto A,Fierro B,Aridon P

更新日期：2017-06-01 00:00:00

abstract：INTRODUCTION:Chronic inflammatory neuropathies are disorders caused by an immune response to peripheral nerve. They include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and neuropathy associated with anti-MAG IgM monoclonal gammopathy and other less frequent neurop...

journal_title：Expert review of neurotherapeutics

authors： Nobile-Orazio E,Gallia F,Terenghi F,Bianco M

更新日期：2017-08-01 00:00:00

abstract：:Alzheimer's disease is the most common form of neurodegenerative dementia and poses considerable health challenges to both patients and their families. Rivastigmine is a powerful slow-reversible, noncompetitive carbamate cholinesterase inhibitor that is approved for the treatment of mild-to-moderate Alzheimer's diseas...

journal_title：Expert review of neurotherapeutics

authors： Desai AK,Grossberg GT

更新日期：2005-09-01 00:00:00

abstract：:Currently approved medications to treat cognitive deficits in Alzheimer's disease are targeting relatively late neurotransmission alterations and, thus, new approaches are needed to improve the observed modest efficacy. Employing various combinations of existing drugs is one way to achieve this aim. We can attempt to ...

journal_title：Expert review of neurotherapeutics

authors： Sobow T

更新日期：2010-05-01 00:00:00

abstract：:Research into what works in depression is in trouble. All treatments appear equally effective and what happens in research trials does not seem to translate into clinical practice or, to put it another way, clinical practice is not reflected in randomized controlled trials. We run the risk of designing cosmetic trials...

journal_title：Expert review of neurotherapeutics

authors： Hatcher S

更新日期：2006-01-01 00:00:00

abstract：:In different study populations, several studies have shown that modest C-reactive protein elevation, in the range of apparently healthy individuals, is a strong predictor of future vascular events. Willcox and colleagues summarize the epidemiological and clinical observations that have led to the enthusiastic suggesti...

journal_title：Expert review of neurotherapeutics

authors： Di Napoli M,Papa F

更新日期：2004-07-01 00:00:00

abstract：:Duloxetine is a serotonin-noradrenaline reuptake inhibitor with indications for use in the short term, continuation and maintenance treatment of major depression. Although clinicians currently have access to a range of medications for the treatment of depression, a significant number of patients fail to respond or rem...

journal_title：Expert review of neurotherapeutics

authors： Bochsler L,Olver JS,Norman TR

更新日期：2011-11-01 00:00:00

abstract：:Pharmacotherapy, psychotherapy and other nonpharmacological interventions are used in patients with major depressive disorder (MDD). However, 50% of the patients with MDD fail to achieve a response to first-line antidepressant treatment. In four of five acute monotherapy studies, once-daily extended-release quetiapine...

journal_title：Expert review of neurotherapeutics

authors： Weisler R,McIntyre RS

更新日期：2013-11-01 00:00:00

abstract：:According to the corticoid receptor hypothesis of depression, hyperactivity of the hypothalamic-pituitary-adrenocortical (HPA) system is one of the major pathophysiological factors for the development of depression and opens a broad range of new antidepressant treatment options that are related to direct interventions...

journal_title：Expert review of neurotherapeutics

authors： Schüle C,Baghai TC,Eser D,Rupprecht R

更新日期：2009-07-01 00:00:00

abstract：:Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that arises as a complication of exposure to dopamine receptor blocking agents. Vesicular monoamine transporter type 2 (VMAT2) inhibitors reduce dyskinesia by decreasing transport of monoamines, including dopamine, into presynaptic vesicles, lea...

journal_title：Expert review of neurotherapeutics

authors： Dorfman BJ,Jimenez-Shahed J

更新日期：2021-01-01 00:00:00